
Medicen
4 rue Léon Jost, Paris, Ile-de-France, 75855, France
Overview
Founded in 2005, the Medicen Paris Region global competitiveness cluster aims to position the Paris Region as a European industrial leader in diagnostic and therapeutic innovation and leading-edge health technologies, thus enabling it to become one of the global centres for translational medicine. Medicen Paris Region’s partnership approach is based on the concept of economic value creation in the Paris Region stimulated by innovation, which forms the very basis of the creation of competitiveness clusters and sets three main priorities. Developing growth and employment in profitable markets in a successful dynamic relationship between YICs/SMEs, large firms and academic laboratories, clinical centres and educational establishments, promoting transfer of innovative technologies. Strengthening international competitiveness for the French “health and leading-edge health technology” sector promoting those involved and stimulating the Paris Region’s capacity for innovation. Helping to increase the attractiveness of the Paris Region and the vitality of its healthcare sector.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 1
Sector focus
- Association
- Health Care
- Non Profit
- Project Management
Investment portfolio
- AlgenScribe
Participated · Equity · Nov 2025
Founded in 2022, AlgenScribe is building an innovative, patented platform that integrates advanced molecular biology tools for gene editing. The company’s technology is currently under development and is supported by several French regional and national innovation programs and incubators. With the fresh capital, AlgenScribe intends to continue refining its platform and, by early 2026, transfer its tools toward ex vivo applications. The startup benefits from backing by entities such as the incubateur Provence Côte d’Azur, Région Sud, Eurobiomed, Medicen, the ANR, Bpifrance and YES Invest. Management has already outlined plans for another fund-raise targeted for late 2026 or early 2027 to accelerate commercialization. The latest financing totals €470,000, providing runway for ongoing R&D and proof-of-concept milestones.
Team
Arnaud Gobet
CEO
LinkedIn